Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G

Little is known about the anti‐tumor activity of humoral immunity in lung cancer patients treated with nivolumab, an immune checkpoint inhibitor. Herein, we report a case of lung cancer with 5% expression of PD‐L1, in which a partial response to nivolumab was sustained for > 7 months. Immunohisto...

Descripción completa

Detalles Bibliográficos
Autores principales: Suyama, Takayuki, Fukuda, Yuichi, Soda, Hiroshi, Ogawara, Daiki, Iwasaki, Keisuke, Hara, Takuya, Yoshida, Masataka, Harada, Tatsuhiko, Umemura, Asuka, Yamaguchi, Hiroyuki, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983224/
https://www.ncbi.nlm.nih.gov/pubmed/29667757
http://dx.doi.org/10.1111/1759-7714.12644
Descripción
Sumario:Little is known about the anti‐tumor activity of humoral immunity in lung cancer patients treated with nivolumab, an immune checkpoint inhibitor. Herein, we report a case of lung cancer with 5% expression of PD‐L1, in which a partial response to nivolumab was sustained for > 7 months. Immunohistochemical analysis of the metastatic lymph node biopsy specimen showed prominent accumulation of plasma cells and immunoglobulin G. These findings suggest that pre‐existing humoral immunity may be worth considering as a candidate therapeutic biomarker of nivolumab in some lung cancer patients.

Ejemplares similares